Understanding SR-17018 and the scheduling question

SR-17018 (also referred to as 5,6-dichloro desmethylchlorphine) is a laboratory research compound first described in the scientific literature as a “G-protein-biased” mu-opioid receptor agonist. In animal studies it has been studied for pain relief with a different side-effect profile than conventional opioids. It has more recently been detected outside the laboratory, which is part of what prompted regulatory attention. This site does not provide sourcing, dosing, or usage information of any kind.

Schedule I is the most restrictive category and is defined, in part, as “no currently accepted medical use.” Placing a compound there can add significant registration, supply, and administrative barriers that make legitimate scientific study slower and harder. Some people report that SR-17018 may have helped them reduce opioid use with reduced withdrawal. Those reports are not clinical proof, but they are a signal that many believe deserves careful research before the compound is prohibited on an emergency basis.

Lived-experience reports can point researchers toward questions worth studying. They can be numerous, consistent, and compelling. But they are not controlled clinical trials: they cannot establish safety, effective dosing, or who might be harmed. The honest position is that these reports are strong enough to justify urgent, compound-specific research — not strong enough to claim SR-17018 is proven safe or effective. Both things are true at once.

The United States is in an opioid crisis and needs more researched options for reducing dependence and withdrawal. If a compound might have an opioid-withdrawal application, the public-health interest is in studying it carefully through lawful channels. Emergency Schedule I placement can chill exactly that research at the moment it is most warranted. Preserving lawful research access keeps the door open to finding out whether the reports hold up.

Because this is a public-health and research-access campaign, not a how-to. We deliberately do not provide vendor names, where to buy, dosing instructions, or synthesis/chemistry instructions beyond the compound's name and identifier. Nothing on this site should be taken as encouragement to obtain or use SR-17018. People experiencing opioid dependence or withdrawal should consult qualified medical professionals.

In short: study it before scheduling it. See the specific asks below — delay or narrow emergency scheduling of SR-17018 specifically, separate it from the other compounds in the notice, publish the compound-specific evidence, involve HHS/FDA scientific review, and preserve lawful research access.